259 results on '"Kukreti V"'
Search Results
2. CyBorD induction therapy in clinical practice
3. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents
4. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure
5. Implementation of a pediatric rapid response team: Experience of the hospital for Sick Children in Toronto
6. PRIMARY CENTRAL NERVOUS SYSTEM POST‐TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (CNS‐PTLD): A 20 YEARS RETROSPECTIVE SINGLE CENTER EXPERIENCE
7. CLINICAL UTILITY OF INTERIM CT SCANS IN PATIENTS RECEIVING CHEMOIMMUNOTHERAPY FOR FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA
8. PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASES
9. PROSPECTIVE VALIDATION OF RECIL RESPONSE CRITERIA: RESULTS OF OBINUTUZUMAB‐GDP AS SALVAGE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN AGGRESSIVE B CELL LYMPHOMA
10. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
11. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
12. A phase II study (PX-171–003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma (RRMM): 14
13. Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) (PX-171-004): A493
14. Retropective Comparison of Engraftment After First and Second Autotransplantations for Relapsed Myeloma: A458
15. Phase II Study of Carfilzomib in Patients with Relapsed Myeloma (PX-171-004): A378
16. Phase I/II Trial of Cyclophosphamide, Prednisone, and Lenalidomide for Relapsed and Refractory MM: A333
17. Bortezomib-Based Therapy Following Prior Lenalidomide + Dexamethasone in Relapsed Multiple Myeloma: A334
18. FUNCTIONAL PREDICTORS OF CHEMOTHERAPY TOXICITY IN ELDERLY LYMPHOMA PATIENTS - A PROSPECTIVE PILOT STUDY
19. PS1376 LENALIDOMIDE MAINTENANCE POSITIVELY IMPACTS OUTCOMES IN MULTIPLE MYELOMA WITHOUT NEGATIVE IMPACTS IN RELAPSE: AN ANALYSIS OF REAL WORLD DATA FROM THE MYELOMA CANADA RESEARCH NETWORK NATIONAL DATABASE
20. EFFICIENCY AND SAFETY OF STEM CELL MOBILIZATION FOLLOWING GDP SALVAGE IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA
21. Carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients with relapsed multiple myeloma: analysis of response and progression-free survival hazard ratio over time
22. Treatment and Outcomes for Primary Cutaneous Extramedullary Plasmacytoma: A Case Series
23. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
24. Outcomes in Stage I-II Diffuse Large B-Cell Lymphoma Presenting With Extradural Involvement at a Single Centre (1995-2010)
25. Long Term Cryopreserved Autologous Blood Stem Cells For Salvage Autologous Stem Cell Transplantation (ASCT) in Relapsed Multiple Myeloma (MM) Patients
26. A Phase 1/2 Trial of the Insulin Growth Factor 1 Receptor (IGF-1R) inhibitor, Linsitinib in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)
27. Myeloma Canada Research Network (MCRN) 001 Trial with Intravenous (IV) Busulfan + Melphalan (BuMel) as Enhanced Conditioning, followed by Lenalidomide (Len) Maintenance in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts): First Results of Minimal Residual Disease (MRD) and Hevylite(TM) Chain (HLC) Assays at Day 100 Post Autologous Stem Cell Transplant (ASCT)
28. Outcome of t(4;14) in Multiple Myeloma – Princess Margaret Cancer Centre Experience Over the Last 10 Years
29. A single centre retrospective analysis of the addition of clarithromycin (biaxin) to lenalidomide and dexamethasone (len-dex) during time of progressive disease in patients with multiple myeloma (MM)
30. A Retrospective Analysis at the Princess Margaret Cancer Centre of the Initial Therapy of AL Amyloidosis: CyBorD versus Other Regimens
31. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating cell free DNA (cfDNA) in multiple myeloma (MM)
32. Wax Content of Crude Oil: A Function of Kinematic Viscosity and Pour Point
33. Systemic Treatment Safety Symposium 2014: Oral Chemotherapy
34. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents
35. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure
36. ABSTRACT 327
37. Toward Successful Migration to Computerized Physician Order Entry for Chemotherapy
38. 020 Best Practices and Performance Measures for Systemic Treatment Perscriber Order Entry Systems (STCPOE) in Chemotherapy Delivery
39. Pattern of Failure in Patients With Stage I-II Hodgkin Lymphoma Treated With CMT: Implications of Partial Nodal Region Coverage and the Need for Adjacent Uninvolved Nodal Region Coverage
40. A Single Institution Experience of Extranodal Natural Killer/T-cell Lymphoma of Nasal Type
41. Studies on Volatile Characteristics of Middle Distillates and Their Interdependency
42. 9219 POSTER Combined Modality Therapy for Stage l-ll Diffuse Large B-cell Lymphoma Provides Excellent Local Control and Clinical Outcome in the Rituximab Era
43. Positron Emission Tomography for Response Assessment of Lymphoma Patients Having Residual Abnormalities following Initial Treatment: The Impact on Clinical Management
44. 9236 Results of PX-171–003-A0, part 1 of an open-label, single-arm, phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma
45. 9201 Tolerability profile of carfilzomib enables full-dose anti-tumor treatment for up to 12 months
46. PX-171–004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update
47. A493 Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) (PX-171-004)
48. A334 Bortezomib-Based Therapy Following Prior Lenalidomide + Dexamethasone in Relapsed Multiple Myeloma
49. A378 Phase II Study of Carfilzomib in Patients with Relapsed Myeloma (PX-171-004)
50. A333 Phase I/II Trial of Cyclophosphamide, Prednisone, and Lenalidomide for Relapsed and Refractory MM
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.